Spots Global Cancer Trial Database for Dose Dense MVAC for Muscle Invasive Bladder Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Dose Dense MVAC for Muscle Invasive Bladder Cancer

Official Title: Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract

Study ID: NCT01031420

Conditions

Muscle Invasive Bladder Cancer

High Risk Urothelial Carcinoma of the Upper Urinary Tracts

Interventions

single arm dose dense MVAC

Study Description

Brief Summary: Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of cure. The M V chemotherapy is usually given every 14 days with the AC given along each 28 days. This study looks at giving the same drugs at the same doses closer together, all drugs every 14 days, with the support of growth factor medication to promote growth of the white blood cells and platelets and allow chemotherapy to be finished sooner and surgery to be done sooner.

Detailed Description: Primary Objective To assess the rate of complete response (pT0) at cystectomy or ureterectomy following preoperative dose dense MVAC (DD-MVAC) in patients with muscle invasive urothelial carcinoma of the bladder or high grade upper tract urothelial carcinoma. Secondary Objectives To assess the toxicity profile of DD-MVAC when given in the neoadjuvant setting: To define the number of patients who complete all three cycles of treatment without dose reduction, and to compare incidence of toxicity to the historical standard described by Grossman et al. To assess the 5 year overall and relapse free survival in patients who receive neoadjuvant DD-MVAC. To compare complete response rates between the following subgroups of study patients: Among bladder patients: Clinical N0 versus N1 (Appendix B) Among bladder patients: T2 stage without high risk features versus T2 with high risk features plus those with \> T2 stage. Three 14 day cycles of: Methotrexate 30 mg/m2 IV push or infusion over 2-3 minutes. Day 1 Vinblastine 3 mg/m2 Slow IV push or infusion over Day 1 Doxorubicin 30 mg/m2 Slow IV push or infusion over 15 minutes Day 1 Cisplatin 70 mg/m2 IV infusion over 4 hours Note: May divide dose over two sequential days (35 mg/m2/d x 2 days) if creatinine clearance 50-59 mL/min Day 1\* (or divided over Day 1 and Day 2) Pegfilgrastim 6 mg subcutaneous (SQ) 24-48 hours after completion of chemotherapy. Followed in 4-8 weeks by radical cystectomy/ureterectomy.